Overview
The NEPTUNUS study and its extension tested the efficacy and safety of Ianalumab (VAY736) in patients with active Sjögren’s disease.
Key Facts
- Status: Active
- Dates: September 2022 – Present
- Principal Investigator: Thomas Grader-Beck, MD
- Sponsor: Novartis Pharmaceuticals
- Location: our branch of the study was conducted at the Johns Hopkins Jerome L. Greene Sjögren’s Center in Baltimore, MD
Study Design
The study involved patients over 18 years of age who were diagnosed with Sjogren’s, had particular clinical findings such as a certain level of salivary flow, and were experiencing higher levels of disease activity.
Results
To view results and ongoing discoveries related to this trial, see the Clinical Trials Page.
Impact
This research has provided valuable knowledge about Sjögren’s disease that is likely to facilitate the development of better treatments, including a specific medication FDA-approved for the disease.
